Biotech News

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Adial Pharmaceuticals (ADIL)Adial Pharmaceuticals2026-06-25 13:46 ESTCompany update

Experts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorder

CHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a...

Open original release

Related news

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss "New Aspects in Substance Use Treatment" at The Annual International Society of Addiction Medicine Conference

ADILAdial Pharmaceuticals2026-06-25 13:46 EST

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

View all latest news

Adial Pharmaceuticals

Adial Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ADILAdial Pharmaceuticals2026-06-26 08:22 EST

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism

ADILAdial Pharmaceuticals2026-06-26 08:22 EST

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ADILAdial Pharmaceuticals2026-06-26 08:22 EST

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

ADILAdial Pharmaceuticals2026-06-26 08:22 EST

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

ADILAdial Pharmaceuticals2026-06-26 08:22 EST

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States